SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Experiment: Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri

experiment 1,093 words KG: PSP 2026-03-30

kind:experiment section:experiments state:published

Contents

Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Trials Have Not Succeeded

Knowledge Graph

Related Hypotheses (27)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36 Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68 Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65 CYP46A1 Overexpression Gene Therapy
Score: 0.63 Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59

PARP1 Inhibition Therapy
Score: 0.58 Competitive APOE4 Domain Stabilization Peptides
Score: 0.56 Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.55 APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54 Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53 GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52 Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51 Ganglioside Rebalancing Therapy
Score: 0.50 Lysosomal Calcium Channel Modulation Therapy
Score: 0.49 Orexin-Microglia Modulation Therapy
Score: 0.49 Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.48 Complement C1q Mimetic Decoy Therapy
Score: 0.48 APOE Isoform Expression Across Glial Subtypes
Score: 0.48 TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.47 Arginine Methylation Enhancement Therapy
Score: 0.46 Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46 Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.45 Hypocretin-Neurogenesis Coupling Therapy
Score: 0.45 HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.44 R-Loop Resolution Enhancement Therapy
Score: 0.43 Glial Glycocalyx Remodeling Therapy
Score: 0.41 SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.39

Related Analyses (22)

4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived Do tau strains or regional cellular environments primarily d
neurodegeneration · failed 4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived

Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived Synaptic pruning by microglia in early AD
neurodegeneration · archived Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived Circuit-level neural dynamics in neurodegeneration
neuroscience · archived Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · completed Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived

Related Experiments (27)

4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40 Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40 Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40 ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40 Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40

PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40 Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40 Tau Spreading Network Mapping via Spatial Transcriptomics in
clinical · proposed · Score: 0.40 s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40 Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40 ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40 ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40 Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40 Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40 Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40 C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40 Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40 FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40 Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40 N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40 Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40 Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40 Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40 Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40 Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40 TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40 Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40

See Also (11)

Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: activates Packard Center for ALS Research
institution · KG edge: expressed_in Dementia Australia
institution · KG edge: associated_with Alzheimer Indonesia
institution · KG edge: associated_with DUSP10 Gene
gene · KG edge: associated_with

cdkn2a
gene · KG edge: associated_with Genes
index · KG edge: activates Autophagy Enhancement Drug Screening for Neurodegenerat
experiment · KG edge: therapeutic_target Apoptosis in Neurodegeneration
entity · KG edge: associated_with Frontotemporal Dementia (FTD)
disease · KG edge: associated_with Amyotrophic Lateral Sclerosis
redirect · KG edge: expressed_in

Knowledge Graph (12 edges)

PSP downregulates SV2A

PSP associated_with SP1

PSP associated_with APOE

PSP associated_with TAU

PSP associated_with KIF13A

PSP associated_with TRIM24

PSP associated_with STX6

PSP associated_with MAPT

PSP activates VPS29

PSP activates MAPT

SciDEX — scidex.ai — Dashboard | Atlas